Paper Details

  1. Home
  2. Paper Details

Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia.

Author: BehmF G, DahlG V, DodgeR K, GeorgeS L, KalwinskyD K, MirroJ, MurphyS B, PuiC H, RaimondiS C, RiveraG K

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

A study of 733 children with acute lymphoid leukemia (ALL) found that intensive chemotherapy treatment increased the risk of developing acute myeloid leukemia (AML) during remission, particularly for patients with a T-cell immunophenotype.
Paper Details　
Original Abstract of the Article :
We studied the risk of the development of acute myeloid leukemia (AML) during initial remission in 733 consecutive children with acute lymphoid leukemia (ALL) who were treated with intensive chemotherapy. This complication was identified according to standard morphologic and cytochemical criteria in...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJM198907203210302

データ提供：米国国立医学図書館（NLM）

Secondary Acute Myeloid Leukemia: A Sandstorm in the Desert of Cancer Treatment

Cancer treatment, like navigating a vast and unforgiving desert, often presents unforeseen challenges and complications. This study focuses on the risk of developing secondary acute myeloid leukemia (AML) in children who have been treated for acute lymphoid leukemia (ALL), a potentially life-threatening complication that can arise during the course of treatment. The researchers explore the prevalence and characteristics of secondary AML in children with ALL, shedding light on this complex and challenging aspect of cancer care.

The Threat of Secondary AML

The study reveals a significant risk of developing secondary AML in children treated for ALL, with a cumulative risk of 1.6% at three years and 4.7% at six years. This finding, like a sudden sandstorm in a seemingly serene desert, underscores the potential for treatment-related complications. The study also highlights the increased risk of secondary AML in patients with a T-cell immunophenotype, emphasizing the need for careful monitoring and personalized treatment approaches. This research, like a beacon of warning in a vast and unforgiving desert, serves as a reminder of the importance of vigilance and continued research in cancer care.

Navigating the Landscape of Cancer Treatment

This research provides valuable insights into the complex landscape of cancer treatment, highlighting the potential for treatment-related complications and the need for careful monitoring and personalized approaches. The findings underscore the importance of ongoing research to understand the mechanisms underlying secondary AML and to develop strategies for prevention and treatment. This study, like a compass guiding a traveler through a treacherous desert, emphasizes the need for continued innovation and vigilance in cancer care.

Dr. Camel's Conclusion

This study sheds light on the potential for secondary acute myeloid leukemia (AML) to arise as a complication of acute lymphoid leukemia (ALL) treatment. The findings underscore the importance of vigilant monitoring and personalized treatment strategies for patients with ALL, as well as the need for ongoing research to understand the underlying mechanisms of secondary AML and develop effective prevention and treatment strategies. This research, like a camel navigating a vast and unpredictable desert, reminds us that cancer care is a complex and challenging journey, requiring a commitment to continuous research, innovation, and compassionate care.

Date :
  1. Date Completed 1989-08-15
  2. Date Revised 2007-11-15
Further Info :

Pubmed ID

2787477

DOI: Digital Object Identifier

10.1056/NEJM198907203210302

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.